Hermès Menswear Marks Historic Transition as Véronique Nichanian Bids Farewell in Paris 
ANTA Sports to Acquire Major Stake in Puma in €1.5 Billion Deal, Signaling Strategic Revival 
ASML’s EUV Monopoly Powers the Global AI Chip Boom 
Delta Air Lines Operates Reduced Flight Schedule as Winter Storm Disrupts U.S. Travel 
Noble Corporation Secures $1.3 Billion in New Contracts, Strengthening Offshore Drilling Backlog 
Zijin Mining Shares Hit Record High on $4 Billion Allied Gold Acquisition 
NTSB Opens Investigation Into Waymo Robotaxis After School Bus Safety Violations in Texas 
Trump Administration Takes Stake in USA Rare Earth to Boost U.S. Critical Minerals Supply 
UK Politicians Call for Full Competition Review of Netflix’s Warner Bros Discovery Deal 
Baker Hughes Reports 11% Rise in Q4 Adjusted Profit Driven by LNG Demand 
Ford and GM Near Financing Deal to Support First Brands Group During Bankruptcy 
Samsung Set to Begin HBM4 Production for Nvidia and AMD 
Hyundai Motor Shares Slide After Trump Signals Higher U.S. Tariffs on South Korean Goods 
Ryanair Profit Slumps in Q3 After Italy Antitrust Fine Despite Revenue Growth 
BYD and Exxon Mobil Strengthen Hybrid Technology Partnership 
Tesla Loses Ground in Europe as BYD Accelerates EV Market Share in 2025 
Geneva, Switzerland - 16 May 2017 - ObsEva SA (Nasdaq: OBSV), a Swiss biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman's reproductive health and pregnancy, today announced that Ben T.G. TAN, VP Commercial & Business Development, will attend the BioEquity Europe 2017 Conference. Ben T.G. TAN will be presenting on Monday May 22nd at 2:20 pm and will be hosting one-on-one meetings at the Marriott Rive Gauche in Paris, France.
About ObsEva
ObsEva is a clinical-stage biopharmaceutical company focused on the clinical development and commercialization of novel therapeutics for serious conditions that compromise a woman's reproductive health and pregnancy. Through strategic in-licensing and disciplined drug development, ObsEva has established a late-stage clinical pipeline with development programs focused on treating endometriosis, uterine fibroids, preterm labor and improving ART outcomes. ObsEva is listed on The NASDAQ Global Select Market and is trading under the ticker symbol "OBSV". For more information, please visit www.ObsEva.com.
###
Media Contact:
Liz Bryan
Spectrum Science
[email protected]
202-955-6222 x2526
Company Contact:
Delphine Renaud
ObsEva, CEO Office
[email protected]
+41 22 552 1550
Attachments:
http://www.globenewswire.com/NewsRoom/AttachmentNg/dc1ce354-aedf-44a9-8a26-fb078684a2ec
